Physician profile
Novera Shahid
NPI 1124683743
$7,342.91
in general payments reported to CMS, 2019-2025
30 companies · $4,876 in 2025
The $4,876 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $163 · 2023: $1,098 · 2024: $1,206 · 2025: $4,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,166 · Honoraria: $1,575 · Travel and Lodging: $337 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,166.19 |
| Honoraria | $1,575.00 |
| Travel and Lodging | $337.21 |
| Education | $101.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $2,301.16 | 2023-2025 | Isturisa, Signifor Lar |
| Corcept Therapeutics | $690.02 | 2023-2025 | Korlym |
| Amgen INC. | $438.68 | 2023-2025 | Tepezza, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $364.00 | 2023-2025 | |
| Kyowa Kirin, INC. | $351.76 | 2023-2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $317.05 | 2022-2025 | |
| Novo Nordisk INC | $307.86 | 2023-2025 | Ozempic, Rybelsus |
| Sequel Med Tech, LLC | $299.67 | 2025 | Twiist |
| Mannkind Corporation | $223.83 | 2023-2025 | V-Go |
| Tandem Diabetes Care, INC. | $218.62 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $192.06 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $183.05 | 2025 | Omnipod |
| Renalytix Ai, INC. | $182.99 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Abbvie INC. | $181.94 | 2024-2025 | |
| Lilly USA, LLC | $160.54 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.14 | 2024-2025 | Jardiance |
| Radius Health, INC. | $133.70 | 2024-2025 | Tymlos |
| Dexcom, INC. | $127.98 | 2023-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $80.74 | 2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $71.14 | 2022-2025 | Licart, Tirosint, Flector |
| Cequr Corporation | $70.44 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $68.39 | 2023-2025 | |
| Medtronic, INC. | $68.05 | 2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $49.36 | 2024 | Strensiq |
| Pfizer INC. | $32.89 | 2023 | |
| Ascendis Pharma Endocrinology INC | $16.45 | 2025 | Yorvipath |
| Averitas Pharma INC. | $15.67 | 2025 | Qutenza |
| Ascensia Diabetes Care US INC. | $15.00 | 2024 | |
| Antares Pharma, INC. | $14.26 | 2025 | Xyosted |
| Lifescan, INC. | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Novera Shahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.